in ,

AstraZeneca Books $60M Army Contract for Coronavirus Antibody Drug Production


The U.S. Army has awarded AstraZeneca a $60M contract to produce an antibody drug for the prevention and treatment of SARS-CoV-2 infections.

The biopharmaceutical company will manufacture at least 100K AZD7442 treatment courses and received half of the total contract value at the time of award, the Department of Defense said Friday.

Work will take place at the drugmaker's facility in Gaithersburg, Maryland, through June 30, 2021.

AstraZeneca began testing its monoclonal antibody combination in August through a clinical trial funded by the Defense Advanced Research Projects Agency and the Biomedical Advanced Research and Development Authority.

ExecutiveBiz Logo

Sign Up Now! ExecutiveBiz provides you with Daily Updates and News Briefings about Contract Awards


Written by Matthew Nelson

Cygnus launch
Northrop Spacecraft On Its Way to ISS for 14th Cargo Resupply Mission
Teresa Carlson VP AWS
AWS’ Teresa Carlson on Federal Cloud Adoption During COVID-19 Pandemic